Combination Chemotherapy of Intermediate and High- Grade Non-Hodgkin's Lymphoma with MACOP-B

African americans treated on SWOG NHL studies: Similar incidence, received dose intensity and outcome to caucasian patients.

S Dahlberg;RI Fisher;CA Coltman ASCO 13:370(#1251)

A predictive model for aggressive non-Hodgkin's lymphoma. THE INTERNATIONAL NON-HODGKIN'S LYMPHOMA PROGNOSTIC FACTORS PROJECT.

NEJM 329(14):987-994

Development of a predictive model for aggressive lymphoma. The International NHL prognostic factors project.

N Shipp;D Harrington;J Anderson;J Armitage;G Bonadonna;G Brittinger;F Cabanillas;G Canellas;R Coiffier;J Connors;R Cowan;C Crowther;M Engelhard;R Fisher;C Gisselbrecht;E Horning;E Lepage;A Lister;J Meerwaldt;E Montserrat;N Nissen;M Oken;B Peterson;C Tondini;W Valasquez;B Yeap ASCO 11:319(#1084)

Combination chemotherapy of intermediate and high grade lymphoma with MACOP-B. A Southwest Oncology Group study.

JK Weick;S Dahlberg;RI Fisher;B Dana;TP Miller;SP Balcerzak;HI Pierce JCO 9(5):748-753

Dose intensity is not associated with subsequent survival after adjustment for known prognostic factors in non-Hodgkin's lymphoma patients treated with m-BACOD, ProMace-CytaBOM, and MACOP-B on Southwest Oncology Group study.

S Dahlberg;TP Miller;B Dana;J Weick;RI Fisher ASCO 9:225(#986)

The treatment of non-hodgkin's lymphoma with m-BACOB,ProMACE-CytaBOM, and MACOP-B: The Southwest Oncology Group (SWOG)experience.

J Weick;S Dahlberg;T Miller;B Dana;R Fisher ASCO 8:254(#990)

Southwest Oncology Group clinical trials for intermediate andhigh grade non-hodgkin's lymphomas.

TP Miller;BW Dana;JK Weick;SE Jones;C Coltman, Jr;S Dahlberg;RI Fisher;S Green;HI Pierce;RW Roach;SP Balcerzak;L Militello Sem Hematol 25(2):17-22

Southwest Oncology Group clinical trials for intermediate andhigh-grade non-hodgkin's lymphomas.

RI Fisher;TP Miller;BW Dana;SE Jones;S Dahlberg;C Coltman, Jr Seminars in Hematology 24(2):21-25

MACOP-B chemotherapy for non-hodgkin's lymphomas: A SWOG Study.

ASH :#852